Lyra Health

Lyra HealthLyra Health
Lyra Health

Lyra Health

AI-powered mental health benefits platform for employers, transforming access to care.

DR 732015Active2853Burlingame, United States
Rate

About

Lyra Health is a leading global provider of workforce mental health care, offering fast access to therapy, coaching, psychiatry, and specialty care. They connect individuals to a vast network of over 30,000 providers and utilize clinically-rigorous AI to enhance care coordination and member matching. Lyra serves individuals, employers, providers, benefit consultants, health plans, and health systems.
Frequently asked

What does Lyra Health do?

Lyra Health is a leading global provider of workforce mental health care, offering fast access to therapy, coaching, psychiatry, and specialty care. They connect individuals to a vast network of over 30,000 providers and utilize clinically-rigorous AI to enhance care coordination and member matching. Lyra serves individuals, employers, providers, benefit consultants, health plans, and health systems.

What is Lyra Health's revenue?

StartupHub estimates Lyra Health's annual revenue at $567.5M (range $291.2M to $959.8M, 65% confidence), based on comparable companies in the sector.

What is Lyra Health's valuation?

StartupHub estimates Lyra Health's effective valuation at $11.2B (range $7.9B to $14.6B, 40% confidence), based on comparable companies in the sector.

How much funding has Lyra Health raised?

Lyra Health has raised a total of $172M in funding. The most recent round on record is Funding Round.

Where is Lyra Health headquartered?

Lyra Health is headquartered in Burlingame, United States.

When was Lyra Health founded?

Lyra Health was founded in 2015.

What industry does Lyra Health operate in?

Lyra Health operates in HealthTech, Mental Health Tech, Employee Benefits, Telemedicine, Digital Health, Enterprise Software.

How many employees does Lyra Health have?

Lyra Health has approximately 2853 people on record.

HEADCOUNT
2853
DOMAIN RATING
73
Comments

No comments yet. Be the first to share your take.